Overview

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).
Phase:
Phase 2
Details
Lead Sponsor:
Axovant Sciences Ltd.